For ads-free news, click here.
The FDA has approved Eli Lilly’s donanemab (Kisunla) for early symptomatic Alzheimer’s disease, marking a significant advancement in Alzheimer’s treatment.
This approval expands treatment options for the approximately 5.7 million people in the U.S. currently living with Alzheimer’s.
Additionally, a groundbreaking trial in South Africa and Uganda has shown that a twice-yearly injection of lenacapavir is 100% effective in preventing HIV infection, offering a new tool in the fight against HIV.
These developments highlight significant progress in the fields of Alzheimer’s and HIV prevention.
Some cases start with a language disorder (logopenic primary progressive aphasia). Others start with a visual agnosia (posterior cortical atrophy); others begin with early executive function deficits (frontal variant).
Heterogeneity of Alzheimer’s disease https://t.co/c59oVSFkCU
— Jesus Ramirez-Bermudez (@JRBneuropsiq) July 5, 2024
A new, FDA-approved drug, Kisunla, produced by Eli Lilly, can slow the brain's decline in the early stages of Alzheimer's. #khou11 @MarcelinoKHOU https://t.co/ynbkHd4sei
— KHOU 11 News Houston (@KHOU) July 5, 2024
